Roivant Sciences Ltd. - Common Shares (ROIV) closed at $41.85 on November 11, 2026, up 1.6% from the previous close, on volume of 6,167,754 shares (30-day average 6,960,226).
Data as of November 11, 2026.
11-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 21, 2026 | Strangle or Risk Reversal | 20-Nov-2635 P : 40 C | 2,000 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 10, 2026. See the 10 largest for 30, 60 and 90 days
Globe Newswire (Tue, 10-Nov 1:24 PM ET)
Analysts Are Bullish on These Healthcare Stocks: Roivant Sciences (ROIV), Neurogene (NGNE)
TipRanks (Tue, 10-Nov 8:20 AM ET)
TipRanks (Tue, 10-Nov 6:50 AM ET)
TipRanks (Tue, 10-Nov 5:30 AM ET)
TipRanks (Mon, 9-Nov 1:20 PM ET)
At a glance: Stocks gapping up premarket
Seeking Alpha News (Mon, 9-Nov 8:50 AM ET)
Roivant Sciences GAAP EPS of -$0.27 beats by $0.09, revenue of $35.12M beats by $31.01M
Seeking Alpha News (Mon, 9-Nov 7:03 AM ET)
Globe Newswire (Mon, 9-Nov 7:00 AM ET)
Globe Newswire (Mon, 9-Nov 7:00 AM ET)
Here are the major earnings before the open Monday
Seeking Alpha News (Sun, 8-Nov 6:04 PM ET)
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
Roivant Sciences Ltd. - Common Shares trades on the NASDAQ stock market under the symbol ROIV.
As of November 11, 2026, ROIV stock price climbed to $41.85 with 6,167,754 million shares trading.
ROIV has a beta of 0.34, meaning it tends to be less sensitive to market movements. ROIV has a correlation of 0.01 to the broad based SPY ETF.
ROIV has a market cap of $30.32 billion. This is considered a Large Cap stock.
Last quarter Roivant Sciences Ltd. - Common Shares reported $35 million in Revenue and -$.27 earnings per share. This beat revenue expectation by $31 million and exceeded earnings estimates by $.19.
In the last 3 years, ROIV traded as high as $42.50 and as low as $8.47.
The top ETF exchange traded funds that ROIV belongs to (by Net Assets): IJH, VTI, VB, XMMO, VBK.
ROIV has outperformed the market in the last year with a price return of +97.7% while the SPY ETF gained +12.6%. ROIV has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +17.0% and +14.5%, respectively, while the SPY returned -1.5% and -1.3%, respectively.
ROIV support price is $40.09 and resistance is $42.29 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ROIV shares will trade within this expected range on the day.
